Pharmaceuticals

Angina Pectoris Drugs Market Trends and Insights: Global Forecast to 2030

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the angina pectoris drugs market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Angina Pectoris Drugs Market reach by 2030 starting from 2026 levels?

The angina pectoris drugs market size has seen robust expansion in recent years. It is projected to grow from $12.88 billion in 2025 to $13.63 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the increasing prevalence of coronary heart disease, rising awareness of angina symptoms, the introduction of beta-blockers, the expansion of hospital infrastructure, and the growing adoption of calcium channel blockers.

The angina pectoris drugs market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $17.67 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. This projected expansion during the forecast period can be linked to developments in precision medicine, the proliferation of wearable cardiac monitoring devices, an increasing need for combination therapies, greater investment in research and development for anti-ischemic agents, and the incorporation of telehealth into cardiac care. Key trends expected during this period involve tailored angina management strategies, less invasive drug delivery methods, fixed-dose combination medications, an expanding elderly patient demographic, and the wider adoption of telemedicine and remote cardiac monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

Which Drivers Are Influencing Long-Term Growth In The Angina Pectoris Drugs Market?

The rising incidence of cardiovascular diseases (CVDs) is projected to stimulate expansion within the angina pectoris drug market. These conditions, which include disorders like coronary artery disease, high blood pressure, heart failure, and stroke, impact the heart and blood vessels. The growing occurrence of CVDs stems from various factors, such as an aging demographic, unhealthy daily habits, and the widespread obesity crisis. Medications for angina pectoris, including nitrates, beta-blockers, and calcium channel blockers, are vital for alleviating chest pain and discomfort resulting from inadequate blood supply to the heart, thus improving patients’ overall well-being. A relevant example from January 2024, as reported by the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the increasing prevalence of cardiovascular diseases is a key factor propelling the growth of the angina pectoris drug market.

How Is The Angina Pectoris Drugs Market Divided Into Segments?

The angina pectoris drugs market covered in this report is segmented –

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins

2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina

3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates

2) By Antiplatelet Agents: Aspirin, Clopidogrel

3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers

4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers

5) By Anti-Ischemic Agents: Ranolazine, Ivabradine

6) By Statins: Atorvastatin, Rosuvastatin

What Trends Are Projected To Support The Growth Of The Angina Pectoris Drugs Market?

Major companies operating in the angina pectoris drug market are focusing on adopting new technologies to maintain their position in the market, exemplified by the U.S. Food and Drug Administration’s approval of Labetalol Hydrochloride Injection for treating angina and to better cater to the needs of their existing consumers. Furthermore, the United States Food and Drug Administration (FDA) has authorized Nitrostat (Nitroglycerin Sublingual Tablets) for both the immediate treatment and acute prevention of angina pectoris. For instance, in March 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched Labetalol Hydrochloride Injection, USP, in a prefilled syringe. This product has also been authorized by the United States Food and Drug Administration. In hospitals, the 10 mg/2 mL PFS is utilized to manage severe hypertension and reduce blood pressure.

Which Major Firms Are Strengthening Their Position In The Angina Pectoris Drugs Market?

Major companies operating in the angina pectoris drugs market are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Lupin Pharmaceuticals Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Servier Laboratories, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., H. Lundbeck A/S

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Angina Pectoris Drugs Market?

North America was the largest region in the angina pectoris drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Angina Pectoris Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10797&type=smp

Browse Through More Reports Similar to the Global Angina Pectoris Drugs Market 2026, By The Business Research Company

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795